You are here

  • Home
  • Archive
  • Volume 77, Issue Suppl 2
  • FRI0122 Drug survival of adalimumab in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis over 10 years in real-world setting of czech registry attra

Article info

Article menu
Download PDFPDF
FRIDAY, 15 JUNE 2018
Rheumatoid arthritis – biological DMARDs
FRI0122 Drug survival of adalimumab in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis over 10 years in real-world setting of czech registry attra

Authors

Citation

Pavelka K, Zavada J, Kristkova Z, et al
FRI0122 Drug survival of adalimumab in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis over 10 years in real-world setting of czech registry attra
Annals of the Rheumatic Diseases 2018;77:605-606.

Publication history

  • First published June 12, 2018.
Online issue publication 
January 09, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© 2018, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions